Trial Profile
Phase II trial of PBI 4050 in patients with diabetic nephropathies.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics; Proof of concept; Therapeutic Use
- 21 Jul 2022 According to Liminal BioSciences media release, the company has discontinued development of fezagepras based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The recommendation to stop the development program for fezagepras was not based on safety concerns.
- 21 Jul 2022 Status changed from planning to discontinued, according to a Liminal BioSciences media release.
- 18 Nov 2016 According to a ProMetic Life Sciences media release, this study is planned to initiate in early next year.